RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts. RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007.

Provectus Pharmaceuticals, Inc. company was founded in 2002 and is based in Knoxville, Tennessee. Provectus Pharmaceuticals, Inc., a development stage company, specializes in oncology and dermatology therapies. The company is conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma, and PH-10 as a topical treatment for psoriasis and atopic dermatitis. It received orphan drug designation from the FDA for its melanoma indication. In addition to its suite of proprietary drugs, Provectus Pharmaceuticals developed various intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts. Repligen Corporation develops novel therapeutics primarily for the treatment of diseases of the central nervous system. The company offers Protein A products, which are used in the production and purification of therapeutic monoclonal antibodies. Repligen also licenses its patent covering the use of CTLA4-Ig, a regulator of the activity of the immune system, and receives royalties from Bristol-Myers Squibb based on their U.S. Sales of Orencia. The company's development stage products include RG1068, human secretin for improved MRI of the pancreas; RG2417, uridine for bipolar depression; HDAC inhibitors for Friedreich's ataxia; and RG-SMA for spinal muscular atrophy. The company sells its Protein A products primarily through value-added resellers, as well as through distributors internationally.

Orchid Cellmark Inc. was founded in 1995 and is headquartered in Princeton, New Jersey. Orchid Cellmark Inc. operates as an international provider of identity DNA testing services for the forensic, immigration, and family relationships markets. The company has laboratories in the United States and the United Kingdom; and offers its services to police forces and other government entities. It also provides non-DNA forensic laboratory services. The company's forensic DNA testing is primarily used to confirm that a suspect committed a particular crime, to exonerate an innocent person, or to establish or maintain databases of individuals convicted of crimes; and family relationship DNA testing is used to establish whether two or more people are genetically related. Its DNA testing is used by individuals and employers in security applications to establish or store a person's genetic profile for identification purposes in the event of an emergency or accident. The company was formerly known as Orchid Biosciences Inc. and changed its name to Orchid Cellmark Inc. in June 2005.

Life Sciences Research stands ready to test everything that humans, animals, and the environment eat, use, and are exposed to. The contract research organization (CRO) performs safety and efficacy tests on pharmaceutical and chemical compounds used in products being developed by drug, agricultural, industrial, and veterinary companies. Life Sciences Research and its subsidiaries provide both large and start-up drugmaker clients worldwide with toxicology, metabolism, and stability studies for preclinical candidates that are applying for product approval. The company was taken private in 2009 after being acquired by Lion Holdings.

Cambridge Laboratories Limited company was founded in 1987 and is now owned by its board of directors. Cambridge Laboratories develops and distributes pharmaceuticals to treat the central nervous system, cancer, vitamin deficiency, and other niches. Its product line includes ImmuCyst (for treatment of superficial bladder cancer), Nabilone (chemotherapy-related nausea and vomiting), and Gelclair (oral ulcers and inflammation). Cambridge Labs has distribution alliances to market its products in over 40 countries.

MacroGenics Inc. company is developing therapeutic treatments for cancer, autoimmune disorders, and infectious diseases. The company is helping researchers from National Institutes of Health and two universities to develop a fully human monoclonal antibody (single disease-cell targeting protein) treatment for the deadly West Nile virus. MacroGenics is also in late development stages for another monoclonal antibody used to treat Type 1 diabetes (also known as juvenile diabetes); the diabetes treatment has received orphan drug status, an FDA designation for rare diseases. Other targeted ailments include cancer, arthritis, and multiple sclerosis.

IS Pharma, formerly known as Maelor, is a UK-based drug and medical device company focused on products for the hospital market; it sells directly in the UK and uses distributors elsewhere. Among its products are Volpex, Haemopressin, and ISOplex, all critical care products used in surgery; Mysoline, an oral treatment for epilepsy; and Cryogesic and Aloxi, two cancer drugs. Maelor outlicenses some products outside its core focus areas to other firms, including its OptiFlo catheter, which is distributed by C.R. Bard. Previously limited primarily to the UK market, the firm bought Swiss drug firm Specialty European Pharma International in 2008, giving it a wider presence in Europe and in North America.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.